$OTLK
Outlook Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012234 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.361M
YoY Change 18.76%
% of Gross Profit
Research & Development $11.20M
YoY Change 0.9%
% of Gross Profit
Depreciation & Amortization $28.66K
YoY Change 156.12%
% of Gross Profit
Operating Expenses $19.56M
YoY Change 76.22%
Operating Profit -$19.56M
YoY Change 7.83%
Interest Expense $347.1K
YoY Change -10.56%
% of Operating Profit
Other Income/Expense, Net $63.62M
YoY Change -2277.63%
Pretax Income $44.41M
YoY Change -314.8%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $44.41M
YoY Change -314.8%
Net Earnings / Revenue
Basic Earnings Per Share $1.91
Diluted Earnings Per Share -$0.89
COMMON SHARES
Basic Shares Outstanding 23.66M 23.41M
Diluted Shares Outstanding 25.48M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.02M
YoY Change -5.0%
Cash & Equivalents $32.02M
Short-Term Investments
Other Short-Term Assets $13.59M
YoY Change 46.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.62M
YoY Change 6.04%
LONG-TERM ASSETS
Property, Plant & Equipment $286.5K
YoY Change 616.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $708.4K
YoY Change -11.7%
Other Assets $479.2K
YoY Change -18.69%
Total Long-Term Assets $1.474M
YoY Change 3.15%
TOTAL ASSETS
Total Short-Term Assets $45.62M
Total Long-Term Assets $1.474M
Total Assets $47.09M
YoY Change 5.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.552M
YoY Change 9.83%
Accrued Expenses $2.681M
YoY Change -67.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $32.43M
YoY Change -6.64%
Total Short-Term Liabilities $42.55M
YoY Change -14.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $88.21M
YoY Change 440956.95%
Total Long-Term Liabilities $88.21M
YoY Change 440956.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.55M
Total Long-Term Liabilities $88.21M
Total Liabilities $130.8M
YoY Change 161.79%
SHAREHOLDERS EQUITY
Retained Earnings -$549.0M
YoY Change 20.67%
Common Stock $465.3M
YoY Change 3.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$83.67M
YoY Change
Total Liabilities & Shareholders Equity $47.09M
YoY Change 5.95%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $44.41M
YoY Change -314.8%
Depreciation, Depletion And Amortization $28.66K
YoY Change 156.12%
Cash From Operating Activities -$19.51M
YoY Change 47.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.308M
YoY Change 30.69%
NET CHANGE
Cash From Operating Activities -19.51M
Cash From Investing Activities
Cash From Financing Activities 4.308M
Net Change In Cash -15.20M
YoY Change 53.27%
FREE CASH FLOW
Cash From Operating Activities -$19.51M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23405637
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13012833
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
234057
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
130128
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
465068636
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
453350281
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-548976181
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467918186
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-83673488
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-14437777
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47091727
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32300601
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11201754
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11101504
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29240046
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21508876
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8360933
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7039901
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19585738
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19158487
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
19562687
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
18141405
us-gaap Operating Expenses
OperatingExpenses
48825784
us-gaap Operating Expenses
OperatingExpenses
40667363
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19562687
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18141405
us-gaap Operating Income Loss
OperatingIncomeLoss
-48825784
us-gaap Operating Income Loss
OperatingIncomeLoss
-40667363
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-57497
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7188
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-85544
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2648
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
404593
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
395537
us-gaap Investment Income Interest
InvestmentIncomeInterest
666199
us-gaap Investment Income Interest
InvestmentIncomeInterest
665459
CY2023Q2 us-gaap Interest Expense
InterestExpense
303
us-gaap Interest Expense
InterestExpense
3156964
us-gaap Interest Expense
InterestExpense
2531022
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-577659
CY2024Q2 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
-7563000
CY2023Q2 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
2910000
otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
1949153
otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
2913000
CY2024Q2 otlk Warrant Related Expenses
WarrantRelatedExpenses
3392444
otlk Warrant Related Expenses
WarrantRelatedExpenses
37490012
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-59454222
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
11749
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9786063
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-37126
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
44409187
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20675108
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-81055195
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45989107
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2800
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2800
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
44409187
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20675108
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81057995
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45991907
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.73
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.73
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23227069
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12844079
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16822774
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12343951
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25476438
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12844079
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16822774
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12343951
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-14437777
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1272611
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11178239
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-24343405
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
85714
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3000000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1310507
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-114288943
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-134236127
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7143
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4750000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1396309
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
44409187
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-83673488
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8736571
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
24292160
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1392393
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-18662513
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15758611
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1383405
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6654286
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10487730
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3302734
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1381805
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20675108
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5502839
us-gaap Net Income Loss
NetIncomeLoss
-81057995
us-gaap Net Income Loss
NetIncomeLoss
-45991907
us-gaap Depreciation And Amortization
DepreciationAndAmortization
85062
us-gaap Depreciation And Amortization
DepreciationAndAmortization
32971
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-577659
us-gaap Paid In Kind Interest
PaidInKindInterest
2681847
us-gaap Paid In Kind Interest
PaidInKindInterest
2529830
us-gaap Share Based Compensation
ShareBasedCompensation
3979427
us-gaap Share Based Compensation
ShareBasedCompensation
4157603
otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
1949153
otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
2913000
otlk Warrant Related Expenses
WarrantRelatedExpenses
37490012
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9786063
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-37126
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-85544
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2648
us-gaap Interest Paid
InterestPaid
1158609
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6006045
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-827163
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
28866
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
232220
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2220
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-26995
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1136993
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1324184
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-64826
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4849715
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51811963
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30232084
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60448635
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27596910
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
30000000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4267
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8669
us-gaap Repayments Of Debt
RepaymentsOfDebt
10220000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
823894
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60444368
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46544347
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8632405
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16312263
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23391982
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17396812
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32024387
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33709075
us-gaap Interest Paid Net
InterestPaidNet
475000
us-gaap Interest Paid Net
InterestPaidNet
1159008
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
7750000
otlk Warrant Liability Incurred But Not Yet Paid
WarrantLiabilityIncurredButNotYetPaid
97730836
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
114954
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
223760
otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
131944
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
294416
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.     Organization and Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In May 2024 the Company received Marketing Authorization from the European Commission for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (“AMD”) in the European Union (“EU”).  Additionally, in July 2024 the Company also received marketing authorization for LYTENAVA™ (bevacizumab gamma) in the United Kingdom (“UK”) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial following discussions with the U.S. Food and Drug Administration (“FDA”) in support of the Company’s Biologics License Application (“BLA”) for ONS-5010. In December 2023, the Company submitted a Special Protocol Assessment (“SPA”) to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA’s requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010 BLA. In January 2024, the Company received confirmation that the FDA has reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA’s requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter (“CRL”). The first subject was enrolled in NORSE EIGHT in January 2024.  In addition, through a Type A meeting and additional interactions, the Company has identified the approaches needed to resolve the chemistry, manufacturing and controls (“CMC”) comments in the CRL.</p>
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-548976181
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of the unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited interim consolidated financial statements, such as the current macroeconomic environment, including as a result of inflation, high interest rates or ongoing overseas conflict, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary.</p>
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
44409187
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20675108
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81057995
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-45991907
CY2024Q2 otlk Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-59393374
CY2024Q2 otlk Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Promissory Notes
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfPromissoryNotes
-7563000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22547187
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20675108
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-81057995
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-45991907
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23227069
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12844079
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16822774
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#WarrantsAndRightsOutstanding
CY2023Q3 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#WarrantsAndRightsOutstanding
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001649989
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13012833
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23405637
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37759
dei Entity Registrant Name
EntityRegistrantName
OUTLOOK THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3982704
dei Entity Address Address Line1
EntityAddressAddressLine1
111 S. Wood Avenue, Unit #100
dei Entity Address City Or Town
EntityAddressCityOrTown
Iselin
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08830
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
619-3990
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OTLK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23655636
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32024387
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23391982
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13593261
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7587216
CY2024Q2 us-gaap Assets Current
AssetsCurrent
45617648
CY2023Q3 us-gaap Assets Current
AssetsCurrent
30979198
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286462
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26172
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
708388
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
793932
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
479229
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
501299
CY2024Q2 us-gaap Assets
Assets
47091727
CY2023Q3 us-gaap Assets
Assets
32300601
CY2024Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
32432000
CY2023Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
35551000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4267
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
31801
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5552484
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6574523
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2680914
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2745740
CY2024Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42553828
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
46732159
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
260395
CY2024Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
87950992
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6219
CY2024Q2 us-gaap Liabilities
Liabilities
130765215
CY2023Q3 us-gaap Liabilities
Liabilities
46738378
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12343951
CY2024Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
562685
CY2024Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
1686684
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25476438
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12844079
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16822774
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12343951
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.73
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.73
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
895177
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
919970
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1107166
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
165192
CY2024Q2 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
399853
CY2023Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1234192
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
278718
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426386
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2680914
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2745740
CY2024Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
32432000
CY2023Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
35551000
CY2021Q1 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2024Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P5Y
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
304
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
116
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1193
CY2023Q2 otlk Finance Lease Cost
FinanceLeaseCost
304
otlk Finance Lease Cost
FinanceLeaseCost
116
otlk Finance Lease Cost
FinanceLeaseCost
1193
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
16459
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
11217
us-gaap Operating Lease Cost
OperatingLeaseCost
38892
us-gaap Operating Lease Cost
OperatingLeaseCost
33650
CY2024Q2 us-gaap Lease Cost
LeaseCost
16459
CY2023Q2 us-gaap Lease Cost
LeaseCost
11521
us-gaap Lease Cost
LeaseCost
39008
us-gaap Lease Cost
LeaseCost
34843
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
286462
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26172
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
292196
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
4267
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.099
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.130
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
116
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1193
us-gaap Operating Lease Payments
OperatingLeasePayments
11799
us-gaap Operating Lease Payments
OperatingLeasePayments
27675
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4267
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8669
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
294416
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1630
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
78091
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
79954
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
81817
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
83680
CY2024Q2 otlk Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
49447
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
374619
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
82423
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
292196
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21250000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
14207622
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1396309
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1381805
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3979427
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4157603
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
otlk-20240630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-24-012234-index-headers.html Edgar Link pending
0001558370-24-012234-index.html Edgar Link pending
0001558370-24-012234.txt Edgar Link pending
0001558370-24-012234-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
otlk-20240630.xsd Edgar Link pending
otlk-20240630x10q.htm Edgar Link pending
otlk-20240630xex10d1.htm Edgar Link pending
otlk-20240630xex10d2.htm Edgar Link pending
otlk-20240630xex31d1.htm Edgar Link pending
otlk-20240630xex31d2.htm Edgar Link pending
otlk-20240630xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
otlk-20240630_cal.xml Edgar Link unprocessable
otlk-20240630_lab.xml Edgar Link unprocessable
otlk-20240630_pre.xml Edgar Link unprocessable
otlk-20240630x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending